Stay updated on Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial
Sign up to get notified when there's something new on the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page.

Latest updates to the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page
- Check4 days agoChange DetectedA new revision tag 'Revision: v3.5.4' appears, replacing the previous 'Revision: v3.5.3'. This indicates a minor update to the page's record rather than a substantive change to the study details.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page’s displayed software/document revision identifier was updated from v3.5.2 to v3.5.3 without changing the underlying study information.SummaryDifference0.0%

- Check33 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.0%

- Check62 days agoChange DetectedStudy Protocol and Statistical Analysis Plan document version updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3. No user-facing content appears to be changed.SummaryDifference0.0%

- Check99 days agoChange DetectedRevision: v3.4.2 is now shown. The previously displayed notices about government funding lapse (v3.4.1) have been removed.SummaryDifference0.3%

Stay in the know with updates to Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page.